Association between Serum Uric Acid Levels and Bone Mineral Density in Postmenopausal Women: A Cross-Sectional and Longitudinal Study.
antioxidant
bone mineral density
hormone replacement therapy
menopause
uric acid
Journal
Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525
Informations de publication
Date de publication:
04 Dec 2021
04 Dec 2021
Historique:
received:
26
10
2021
revised:
29
11
2021
accepted:
01
12
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
Uric acid is one of natural antioxidants in human body. There have been several studies on the correlation between uric acid with oxidative stress and osteoporosis. However, the data are insufficient and results are controversial. In this regard, we determined the association between uric acid levels and bone mineral density (BMD) during the postmenopausal period. We analyzed data from 328 postmenopausal women (mean age, 57.3 ± 6.5 years; mean serum uric acid level, 4.6 ± 1.0 mg/dL). The participants were divided into three groups based on tertiles of the serum uric acid level. The participants receiving hormone replacement therapy (HRT), bisphosphonates, or lipid-lowering agents were included. Blood urea nitrogen, serum creatinine, and serum triglyceride levels were significantly higher in the upper tertiles of uric acid levels. No significant difference was found in the mean uric acid levels between medication users and non-users. Each HRT regimen had a different mean serum uric acid level. A cross-sectional analysis showed no significant correlation between the serum uric acid levels and BMD in the spine and femoral neck (spine BMD: 1.050 ± 0.131, 1.060 ± 0.160, 1.084 ± 0.140, Serum uric acid level is not associated with BMD in postmenopausal women.
Sections du résumé
BACKGROUND
BACKGROUND
Uric acid is one of natural antioxidants in human body. There have been several studies on the correlation between uric acid with oxidative stress and osteoporosis. However, the data are insufficient and results are controversial. In this regard, we determined the association between uric acid levels and bone mineral density (BMD) during the postmenopausal period.
METHODS
METHODS
We analyzed data from 328 postmenopausal women (mean age, 57.3 ± 6.5 years; mean serum uric acid level, 4.6 ± 1.0 mg/dL). The participants were divided into three groups based on tertiles of the serum uric acid level. The participants receiving hormone replacement therapy (HRT), bisphosphonates, or lipid-lowering agents were included.
RESULTS
RESULTS
Blood urea nitrogen, serum creatinine, and serum triglyceride levels were significantly higher in the upper tertiles of uric acid levels. No significant difference was found in the mean uric acid levels between medication users and non-users. Each HRT regimen had a different mean serum uric acid level. A cross-sectional analysis showed no significant correlation between the serum uric acid levels and BMD in the spine and femoral neck (spine BMD: 1.050 ± 0.131, 1.060 ± 0.160, 1.084 ± 0.140,
CONCLUSIONS
CONCLUSIONS
Serum uric acid level is not associated with BMD in postmenopausal women.
Identifiants
pubmed: 34946407
pii: healthcare9121681
doi: 10.3390/healthcare9121681
pmc: PMC8701215
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Diabetol Metab Syndr. 2012 Apr 04;4:12
pubmed: 22475652
Obstet Gynecol Sci. 2015 Jan;58(1):46-52
pubmed: 25629018
Am J Obstet Gynecol. 2006 Feb;194(2 Suppl):S3-11
pubmed: 16448873
J Bone Miner Res. 2015 Jun;30(6):992-9
pubmed: 25491196
Curr Pharm Des. 2005;11(32):4117-24
pubmed: 16375732
Clin Rheumatol. 2018 Sep;37(9):2529-2538
pubmed: 29790110
J Lipid Res. 2003 Mar;44(3):512-21
pubmed: 12562831
Biochem J. 1999 May 15;340 ( Pt 1):143-52
pubmed: 10229669
Mol Cell Biochem. 2018 Jun;443(1-2):111-119
pubmed: 29075989
J Pediatr. 2012 Oct;161(4):753-6.e2
pubmed: 22575243
Calcif Tissue Int. 1981;33(3):195-8
pubmed: 6456054
Osteoporos Int. 2016 Mar;27(3):1031-1039
pubmed: 26588908
Osteoporos Int. 2014 Mar;25(3):1099-105
pubmed: 24318630
Mult Scler Relat Disord. 2016 Sep;9:17-22
pubmed: 27645338
Rheumatology (Oxford). 2009 Mar;48(3):222-6
pubmed: 19109320
J Clin Endocrinol Metab. 1994 Oct;79(4):950-4
pubmed: 7962303
JAMA. 1993 Jul 21;270(3):354-9
pubmed: 8315780
Cleve Clin J Med. 2008 Jul;75 Suppl 5:S13-6
pubmed: 18822470
Diabetes Care. 2008 Feb;31(2):361-2
pubmed: 17977935
Proc Natl Acad Sci U S A. 1981 Nov;78(11):6858-62
pubmed: 6947260
J Clin Invest. 2003 Sep;112(6):915-23
pubmed: 12975476
J Diabetes Res. 2020 Jun 13;2020:3982831
pubmed: 32626779
Physiology (Bethesda). 2005 Apr;20:125-33
pubmed: 15772301
Bone. 2013 Jan;52(1):400-6
pubmed: 23111314
Osteoporos Int. 2008 Feb;19(2):211-9
pubmed: 17846860
Int J Endocrinol. 2020 Jun 29;2020:3082318
pubmed: 32676109
J Bone Miner Res. 2011 May;26(5):955-64
pubmed: 21541998
Curr Top Med Chem. 2015;15(21):2233-8
pubmed: 26059354
Am J Clin Nutr. 2009 Jan;89(1):416-24
pubmed: 19056581
Bone. 2015 Oct;79:183-9
pubmed: 26079996
Nutr Metab (Lond). 2004 Oct 19;1(1):10
pubmed: 15507132
Arthritis Rheum. 1995 May;38(5):628-32
pubmed: 7748218
Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1219-25
pubmed: 25192804
Clin Chem. 1998 Jun;44(6 Pt 1):1309-15
pubmed: 9625058
J Ayub Med Coll Abbottabad. 2008 Jan-Mar;20(1):48-51
pubmed: 19024185
Clin Chim Acta. 2008 Jun;392(1-2):1-7
pubmed: 18348869
Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14351-6
pubmed: 20660758
BMC Musculoskelet Disord. 2007 Dec 19;8:124
pubmed: 18088440
Osteoporos Int. 2013 Dec;24(12):2961-70
pubmed: 23644878
Am J Manag Care. 2005 Nov;11(15 Suppl):S435-42; quiz S465-8
pubmed: 16300457
Menopause. 2018 Jan;25(1):77-81
pubmed: 28796699
Endocr Metab Immune Disord Drug Targets. 2018;18(3):251-259
pubmed: 29437024
Curr Pharm Des. 2005;11(32):4145-51
pubmed: 16375736
Menopause. 2015 Dec;22(12):1335-42
pubmed: 25968834
Oncotarget. 2015 Nov 3;6(34):35395-403
pubmed: 26496032
Clin Rheumatol. 2017 Dec;36(12):2637-2644
pubmed: 28980141